# Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

> **NCT01073865** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 222 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ZD9393 (Zoladex) 10.8 mg
- **DRUG:** ZD9393 (Zoladex) 3.6 mg

## Key facts

- **NCT ID:** NCT01073865
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-26
- **Primary completion:** 2012-09-19
- **Final completion:** 2017-11-20
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2018-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073865, "Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01073865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*